|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
Kinase Fusions in ESR1 Wild-Type Metastatic Breast Cancer [ESMO]
|
|
|
|
|
|
As an effort to identify additional therapeutic options which may provide substantial clinical benefit, the study team advocates that molecular testing in metastatic breast cancer at progression after endocrine therapy should include fusion testing, especially in case of absence of ESR1 hotspot alterations.
|
|
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
|
|
|
5.9.12 AACR - BIOPSIES LIQUIDES
|
|
|
|
|
5.9.3 AACR - MÉLANOME
|
|
|